Previous close | 24.64 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 1,691 |
Market cap | 14.147M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | 2.81 |
EPS (TTM) | 0.09 |
Earnings date | 01 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors.
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
SAN DIEGO, May 24, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 1:30pm Eastern Time (10:30am Pacific Time).
According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 03, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2023 and reaffirmed its financial guidance for the year ending December 31, 2023.
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 20, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 4:40pm Eastern Time (1:40pm Pacific Time).
SAN DIEGO, April 17, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. Results demonstrate the positive clinical impact of the system’s automatic correction bolusing on glucose control across a wide range of ages and demographics of people living with type 1 d
SAN DIEGO, April 11, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2023 financial and operating results.
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.
SAN DIEGO, March 15, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range* in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology** compared to those on a standard insulin pump
Some of Wall Street's predictions seem a bit aggressive, but investors should still consider this company.
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, February 22, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem’s Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board.
SAN DIEGO, February 22, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2022 and provided its financial guidance for the year ending December 31, 2023.
SAN DIEGO, February 15, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
With that in mind, let's look at two growth stocks that fit the bill: Tandem Diabetes Care (NASDAQ: TNDM) and Fiverr (NYSE: FVRR). Medical device specialist Tandem Diabetes Care focuses on the diabetes market, as its name suggests. The company has been an innovator in the field, and right now, it makes money by selling its prized insulin pump, the t:slim X2.
SAN DIEGO, January 23, 2023--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced the completion of its previously announced acquisition of AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump. The Sigi Patch Pump, designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges, is under development and not commercially available
SAN DIEGO, January 19, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.
SAN DIEGO, January 10, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its preliminary, unaudited sales for the fourth quarter and year ended December 31, 2022 and worldwide sales outlook for the year ending December 31, 2023.
SAN DIEGO, January 03, 2023--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 8:15pm Eastern Time (5:15pm Pacific Time).